Bargain price Pradaxa secured reimbursement in New Zealand
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim offered to provide its warfarin replacement blood thinner Pradaxa (dabigatran) to authorities in New Zealand at half its US price and then offered a further discount, according to Pharmac, New Zealand's pharmaceutical management agency. The price was an influential factor in the agency's decision to reimburse it, says the agency.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.